RBC Capital lowered the firm’s price target on Surgery Partners (SGRY) to $35 from $49 and keeps an Outperform rating on the shares. The firm is updating its model after the company’s Q3 earnings miss earlier this month, though it remains confident in the management’s development strategy with sufficient liquidity and cash flow to fund future growth for Surgery Partners, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGRY:
- Surgery Partners post-earnings selloff overdone, says Macquarie
- Surgery Partners price target lowered to $31 from $32 at Barclays
- Surgery Partners price target lowered to $34 from $35 at Macquarie
- Surgery Partners Reports Q3 Revenue Growth Amid Challenges
- Surgery Partners reports Q3 adjusted EPS 19c, consensus 25c
Questions or Comments about the article? Write to editor@tipranks.com